BMY, Otsuka submit aripiprazole MAA

Bristol-Myers (BMY) and partner Otsuka (Tokyo, Japan) submitted an MAA to the EMEA for aripiprazole, a once daily small molecule partial agonist of dopamine D2 receptors, to treat schizophrenia. The p...